Clinical trials: Solid Tumors, completed
Colorectal Cancer, Lung Cancer
Lapatinib and Cetuximab in Patients With Solid Tumors
This trial is for patients with colon cancer, head and neck cancer and lung cancer that has not responded to standard therapy. Cetuximab targets a receptor on cancer cells called the Epidermal Growth Factor Receptor or EGFR.
- Conditions
- Colorectal Cancer, Lung Cancer, Head and Neck Cancer
- Trial name
- TYKERB-ITUX 1 (NCT01184482)
- Testing
- cetuximab and lapatinib
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Georgetown University
Cancer
Study of Oral PQR309 in Patients With Advanced Solid Tumors
This is an open-label, multi-center, non-randomized, dose escalation Phase 1 study evaluating safety, tolerability, PK (pharmacokinetics) and efficacy of PQR309 in the treatment of selected patients with advanced solid tumors.
- Trial name
- NCT02483858
- Testing
- PQR 309
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- PIQUR Therapeutics AG
Advanced Solid Tumors
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
The proposed clinical trial is a phase I, open-label, multi-center, dose-escalation study of ALT-803 in patients with surgically incurable advanced solid tumors: melanoma, renal cell, non-small cell lung and squamous cell head…
- Trial name
- NCT01946789
- Testing
- ALT-803
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Breast Cancer, Colorectal Cancer
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
RATIONALE: Sorafenib and pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00703638
- Testing
- cisplatin, pemetrexed disodium, sorafenib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Solid Tumor Malignancies
Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
This protocol will examine the safety of intratumoral administration of Clostridium Novyi-NT spores in patients with treatment-refractory solid tumor malignancies. This investigational study will measure anti-tumor activity of C.
- Trial name
- NCT01924689
- Testing
- Clostridium novyi-NT spores
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- BioMed Valley Discoveries, Inc
Solid Tumor
Intestinal Microbiome Modification With Resistant Starch in Patients Treated With Dual Immune Checkpoint Inhibitors
This is a pilot study designed to assess the safety and feasibility of administering a dietary supplement to patients undergoing cancer treatment with a dual immune checkpoint inhibitors (ICIs) for solid cancer.
- Trial name
- NCT04552418
- Testing
- Potato starch
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Michigan Rogel Cancer Center
Neoplasms
Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)
This is a safety, efficacy, and pharmacokinetics (PK) study of vibostolimab (MK-7684) as monotherapy and in combination with pembrolizumab (MK-3475) or pembrolizumab plus pemetrexed and carboplatin in adults with metastatic solid…
- Trial name
- NCT02964013
- Testing
- vibostolimab, pembrolizumab, pemetrexed
- Volunteers
- 474 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, Adult
Phase 1a Study to Evaluate Immunogenicity of ASV®
This is an open-label Phase 1a First-in-Human Study to determine Safety and Tolerability of ASV® AGEN2017 with QS-21 Stimulon® Adjuvant as a Single Agent in Subjects With Tumors at Risk of Relapse Undergoing Observation as…
- Trial name
- NCT03673020
- Testing
- ASV® AGEN2017 + QS-21 Stimulon® adjuvant
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Agenus Inc.
MDS, AML
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
The purpose of this study is to evaluate three things. The first being whether azacitidine is absorbed in the body at the same rate or proportion for different concentrations.
- Conditions
- MDS, AML, Solid Tumors, Multiple Myeloma
- Trial name
- RENAL (NCT00652626)
- Testing
- azacitidine
- Where
- 11 sites in United States
- Volunteers
- 31 people
- Sponsor
- Celgene
Neoplasms
A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
This is an open-label, multicenter study designed to assess the safety, pharmacokinetics, pharmacodynamics, and therapeutic activity of emactuzumab and RO7009789 administered in combination in participants with locally advanced…
- Trial name
- NCT02760797
- Testing
- Emactuzumab, RO7009789
- Where
- 6 sites in United States, Belgium and 1 more
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors
A Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV in Advanced Solid Tumors
This is a dose-escalation and expansion, open label, single centre, phase Ib study. In this study, the tolerability, safety, pharmacokinetics and efficacy of irinotecan hydrochloride liposome injection in combination with 5-FU/LV…
- Trial name
- NCT05086848
- Testing
- Irinotecan liposome、5-fluorouracil、Leucovorin
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Cancer
Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement
The goal of this clinical research study is find the highest tolerated dose of paclitaxel that can be given directly into the liver of patients with advanced cancer involving the liver.
- Trial name
- NCT00508326
- Testing
- Paclitaxel
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma, Malignant Melanoma
Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies
The purpose of this study is to test if the levels of AZD6244 in blood are affected by taking food at the same time as the capsules compared to taking capsules on an empty stomach
- Trial name
- NCT00710515
- Testing
- AZD6244
- Where
- 6 sites in Netherlands, United Kingdom
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Malignant Neoplasm, Unspecified Adult Solid Tumor, Protocol Specific
Cognitive Assessments in Patients With Cancer Undergoing Chemotherapy
This pilot clinical trial studies cognitive assessments in patients with cancer undergoing chemotherapy. Questionnaires that measure cognitive changes during chemotherapy may help identify the side effects of chemotherapy.
- Trial name
- NCT01506440
- Testing
- cognitive assessment, quality-of-life assessment
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Wake Forest University Health Sciences
Neoplasms, Solid Tumors
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors
This is a Phase 1 dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of BMS-754807 in patients with advanced or metastatic solid tumors.
- Conditions
- Neoplasms, Solid Tumors, Metastases
- Trial name
- NCT00569036
- Testing
- BMS-754807
- Where
- 5 sites in Australia
- Volunteers
- 63 people
- Sponsor
- Bristol-Myers Squibb
Melanoma, Non Small Cell Lung Cancer
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, High Grade Serous Adenocarcinoma of Ovary
- Trial name
- PRESERVE-009 (NCT05858736)
- Testing
- AI-061
- Where
- 5 sites in Australia
- Volunteers
- 18 people
- Sponsor
- OncoC4, Inc.
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Quit2Heal Smartphone App in Helping Cancer Patients Quit Smoking
This phase III trial compares the Quit2Heal smoking cessation smartphone application (app) to the QuitGuide app in helping cancer patients quit smoking.
- Trial name
- NCT04409236
- Testing
- Quit2Heal, QuitGuide, Survey Administration
- Where
- United States
- Volunteers
- 427 people
- Sponsor
- Fred Hutchinson Cancer Center
Advanced Cancers, Solid Tumors
Erlotinib in Combination With Pralatrexate in Advanced Malignancies
The goal of this clinical research study is to find the highest tolerable dose of the combination of erlotinib and pralatrexate that can be given to patients with advanced cancer.
- Trial name
- NCT01532011
- Testing
- Erlotinib, Pralatrexate
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric Cancer, Hepatocellular Carcinoma
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
This is a Phase II, open-label, single dose level study of PRL3-ZUMAB monotherapy in patients with advanced solid tumours that have failed standard therapy.
- Conditions
- Gastric Cancer, Hepatocellular Carcinoma, Advanced Solid Tumor
- Trial name
- NCT04118114
- Testing
- PRL3-zumab
- Where
- Singapore
- Volunteers
- 14 people
- Sponsor
- National Cancer Centre, Singapore
Ototoxicity, Unspecified Adult Solid Tumor
Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin
RATIONALE: Alpha-lipoic acid may prevent or lessen hearing loss caused by cisplatin. PURPOSE: This randomized clinical trial is studying the effectiveness of alpha-lipoic acid in preventing hearing loss in cancer patients…
- Trial name
- NCT00477607
- Testing
- alpha-lipoic acid, Audiology, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- US Department of Veterans Affairs
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.